BEIJING, March 23 /PRNewswire/ --
BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.
BioDuro will provide integrated research services in the areas of discovery chemistry, discovery biology, ADMET*, and DMPK** services, to help enhance internal drug discovery and shorten development timelines.
After a successful collaboration involving discovery chemistry, ADMET, and DMPK, AstraZeneca has expanded its collaboration with BioDuro to leverage the strengths of its team to help develop new therapeutics, said Lena Martensson Director of Strategic Planning and Business Development.